Literature DB >> 7616005

Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.

Z Bata-Csorgo1, C Hammerberg, J J Voorhees, K D Cooper.   

Abstract

An early cellular event in the development of psoriatic lesions is infiltration of target tissue by macrophages and activated T lymphocytes. Lesional psoriatic skin contains activated memory T lymphocytes with production of mRNA for lymphokines such as interleukin-2, interferon-gamma, and tumor necrosis factor-alpha that is elevated relative to normal or uninvolved psoriatic skin. That the T-cell activation and cellular lymphokine production have a crucial role in the maintenance of epidermal hyperplasia in the psoriatic lesion is indicated by the beneficial effect of immunosuppressive agents in the treatment of psoriasis (cyclosporin A, FK506, anti-CD3, anti-CD4). A link between immune activation and psoriasis is also indicated by immunogenetic associations in this disease. Also, psoriatic keratinocytes appear to have been modulated by T-cell lymphokines in vivo, because they abnormally express molecules uniquely induced on keratinocytes by the T-cell product interferon-gamma. Indeed, T cells producing interferon-gamma have been cloned from psoriatic lesions, and they are able to induce keratinocyte class II major histocompatibility complex and intercellular adhesion molecule expression. These lesion-derived T-cell clones can induce growth of keratinocytes, and specifically lesional psoriatic T cells produce factors that induce increased keratinocyte colony formation, as well as increased cell cycle entry of the normally quiescent stem cell population. Interferon-gamma, although a growth inhibitor on its own, acts cooperatively with other T-cell-produced growth factors to cause keratinocyte growth induction. Furthermore, relative to normal stem cells, keratinocyte stem cells (beta 1 integrin+ K1/K10-) in psoriatic uninvolved epidermis are significantly hyperresponsive to the growth-stimulatory lymphokine milieu created by lesional T lymphocytes. Whether such abnormalities in responsiveness are associated with new genetic linkages reported in families of psoriasis patients is unknown. As the epidermis of lesional psoriatic skin can be demonstrated to produce elevated levels of factors that can further potentiate T-cell activation, a self-sustaining cycle can be constructed of T-cell recruitment, intralesional activation, release of factors that preferentially stimulate psoriatic epidermal stem cells to proliferate, and further epidermal potentiation of the T-cell-mediated lesions.

Entities:  

Mesh:

Year:  1995        PMID: 7616005     DOI: 10.1111/1523-1747.ep12316121

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice.

Authors:  N L Ward; C M Loyd; J A Wolfram; D Diaconu; C M Michaels; T S McCormick
Journal:  Br J Dermatol       Date:  2011-04       Impact factor: 9.302

2.  Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration.

Authors:  Ashay K Vaishnaw; Christopher N TenHoor
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

3.  CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis.

Authors:  A Koreck; A Surányi; B J Szöny; A Farkas; Z Bata-Csörgö; L Kemény; A Dobozy
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  Ozonated autohemotherapy elevates PPAR-γ expression in CD4+ T cells and serum HDL-C levels, a potential immunomodulatory mechanism for treatment of psoriasis.

Authors:  Jinrong Zeng; Zhen Tang; Yuezhong Zhang; Xiaoliang Tong; Jianhua Dou; Lihua Gao; Shu Ding; Jianyun Lu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

5.  Fibronectin and alpha5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis.

Authors:  Z Bata-Csorgo; K D Cooper; K M Ting; J J Voorhees; C Hammerberg
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

6.  [Anaplastic large cell lymphoma and keratoacanthoma].

Authors:  M Tronnier; H Merz
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

7.  Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.

Authors:  Lazaro E Aira; Alejandro López-Requena; Dasha Fuentes; Liset Sánchez; Teresita Pérez; Aleida Urquiza; Heber Bautista; Leopoldina Falcón; Patricia Hernández; Zaima Mazorra
Journal:  MAbs       Date:  2014-03-04       Impact factor: 5.857

Review 8.  Topical treatments for scalp psoriasis.

Authors:  Justin Gabriel Schlager; Stefanie Rosumeck; Ricardo Niklas Werner; Anja Jacobs; Jochen Schmitt; Christoph Schlager; Alexander Nast
Journal:  Cochrane Database Syst Rev       Date:  2016-02-26

9.  Plasmin plays an essential role in amplification of psoriasiform skin inflammation in mice.

Authors:  Qun Li; Fang Ke; Weiwei Zhang; Xiaoyan Shen; Qiannan Xu; Hong Wang; Xue-Zhong Yu; Qibin Leng; Honglin Wang
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

10.  Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor.

Authors:  Marjan de Groot; Marcel B M Teunissen; Jean P Ortonne; Julien R Lambert; Jean M Naeyaert; Daisy I Picavet; M Gladys Arreaza; Jason S Simon; Maarten Kraan; Jan D Bos; Menno A de Rie
Journal:  Arch Dermatol Res       Date:  2007-07-24       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.